Skip to main content
Search
Main content
Brain Communications
Published

Clusterin accumulates in synapses in Alzheimer's disease and is increased in apolipoprotein E4 carriers

Authors

Rosemary J Jackson, Jamie Rose, Jane Tulloch, Christopher M. Henstridge, Colin Smith, Tara L Spires-Jones

Abstract

One of the major challenges in developing effective therapeutic strategies for Alzheimer’s disease is understanding how genetic risk factors contribute to neurodegeneration. The apolipoprotein epsilon 4 isoform (APOE4) and variants in the Clusterin (CLU) gene (also known as apolipoprotein J) are associated with increased risk of developing Alzheimer’s. Our previous work demonstrated that APOE4 exacerbates synapse degeneration and synaptic accumulation of toxic oligomeric amyloid beta in human Alzheimer’s and mouse models of disease. Here, we observe clusterin in synapses in human Alzheimer's disease brain. The percentage of synapses containing clusterin is higher in APOE4 carriers than APOE3 carriers. Furthermore, we observe oligomeric amyloid beta accumulation within synapses containing clusterin which is also higher in APOE4 carriers. These data link two genetic risk factors with synapse degeneration in Alzheimer’s and support a potential role for clusterin working with APOE in causing synaptic damage.

UK DRI Authors

Tara Spires-Jones

Prof Tara Spires-Jones

Group Leader

Deciphering why synapses and neurons degenerate and whether boosting resilience of synapses can protect the brain

Prof Tara Spires-Jones